TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of $0.14, $0.23 worse than the analyst estimate of $0.37. Revenue for the quarter came in at $192.57 million versus the consensus estimate of $188.73 million.

GUIDANCE:

TG Therapeutics sees FY2026 revenue of $875-900 million, versus the consensus of $897.6 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.